We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Medical Device Stocks with Solid Potential to Buy Now
Read MoreHide Full Article
The United States boasts being the biggest MedTech market to date and is highly regarded for its innovation and technologically-advanced products across the world. A Kaloroma Information article validates the country’s dominance in the field, thanks to its more than $180 billion in revenues generated from all over the world.
Medical Device Tax Suspension
The medical device industry is booming with possibilities, courtesy of the two-year suspension of the infamous 2.3% Medical Device tax. The lifting of the tax makes scope for solid research and development (R&D), which is likely to benefit companies in the long run.
The 2.3% excise tax was implemented in 2013 under Obamacare, significantly affecting R&D. Per the Advanced Medical Technology Association lobbying group, this tax impaired medical innovation to a great extent, resulting in loss or lower job creation.
To address the problems, the senate placed a temporary suspension on these taxes in the January 2016-December 2017 period.
The taxes were imposed again on Jan 1, 2018, only to be suspended on Jan 22 for another two years. The device tax suspension is one of the very few amendments to see a landslide bipartisan win in the House.
Since Jan 22, the Medical Products industry has rallied 2.2%, significantly outperforming the S&P 500 index’s decline of 4% on account of political, cultural and legal troubles plaguing the markets worldwide.
Making the Right Picks
Against this backdrop, a few medical device stocks are well positioned on strong fundamentals and solid R&D prospects. We have used the Zacks Stock Screener to pick such stocks. We have also taken care to include stocks with a Zacks Rank #1 (Strong Buy) or 2 (Buy) along with a Growth Score of A or B. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 or 2 are better picks than most.
Intuitive Surgical, Inc. (ISRG - Free Report) has a Growth Score of B.
In the past three months, shares of Intuitive Surgical have gained 10.1%, outperforming the industry’s decline of 13.7%.
The California-based company, with a Zacks Rank #1, recently announced that it is commencing direct operations in India through distributor Vattikuti Technologies Pvt. Ltd. Moreover, the company’s flagship da Vinci SP surgical system for urologic surgical procedures was recently approved by the FDA.
In the last 60 days, the Zacks Consensus Estimate for Intuitive Surgical’s earnings per share rose 3.8% to $2.43.
In the past three months, shares of Abiomed have gained 38.5%, outperforming the industry’s decline of 13.7%.
The Massachusetts-based company recently replaced Wyndham Worldwide Corp. on the S&P 500 list.
In the last 60 days, the Zacks Consensus Estimate for Abiomed’s earnings per share rose 1.3% to 80 cents.
Varian Medical Systems, Inc. has a Zacks Rank #2 and a Growth Score of B.
In the past six months, shares of Varian Medical have rallied 7.6%, faring better than the industry’s fall of 7.2%.
The California-based provider of radiotherapy solutions has of late been targeting expansion in Africa. The company’s coveted Halcyon system has been adopted by three different cancer centers in northern and southern Africa. Furthermore, Varian Medical recently signed a software technology training and education cooperation agreement with the Brazil Ministry of Health (MOH) and seven universities and science and technology institutions (ICTs) in Brazil.
Over the last 60 days, the Zacks Consensus Estimate for Varian Medical’s earnings per share remained stable.
Surmodics, Inc. (SRDX - Free Report) has a Zacks Rank #2 and a Growth Score of A.
In the past six months, shares of Surmodics have gained 60.2%, outperforming the industry’s growth of 10.1%.
The Minnesota-based provider of medical device recently signed an agreement with Embolitech to acquire an innovative thrombectomy platform technology and related intellectual property with broad potential peripheral vascular applications. It will enhance the company’s focus on developing highly differentiated whole-product solutions.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
4 Medical Device Stocks with Solid Potential to Buy Now
The United States boasts being the biggest MedTech market to date and is highly regarded for its innovation and technologically-advanced products across the world. A Kaloroma Information article validates the country’s dominance in the field, thanks to its more than $180 billion in revenues generated from all over the world.
Medical Device Tax Suspension
The medical device industry is booming with possibilities, courtesy of the two-year suspension of the infamous 2.3% Medical Device tax. The lifting of the tax makes scope for solid research and development (R&D), which is likely to benefit companies in the long run.
The 2.3% excise tax was implemented in 2013 under Obamacare, significantly affecting R&D. Per the Advanced Medical Technology Association lobbying group, this tax impaired medical innovation to a great extent, resulting in loss or lower job creation.
To address the problems, the senate placed a temporary suspension on these taxes in the January 2016-December 2017 period.
The taxes were imposed again on Jan 1, 2018, only to be suspended on Jan 22 for another two years. The device tax suspension is one of the very few amendments to see a landslide bipartisan win in the House.
Since Jan 22, the Medical Products industry has rallied 2.2%, significantly outperforming the S&P 500 index’s decline of 4% on account of political, cultural and legal troubles plaguing the markets worldwide.
Making the Right Picks
Against this backdrop, a few medical device stocks are well positioned on strong fundamentals and solid R&D prospects. We have used the Zacks Stock Screener to pick such stocks. We have also taken care to include stocks with a Zacks Rank #1 (Strong Buy) or 2 (Buy) along with a Growth Score of A or B. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 or 2 are better picks than most.
Intuitive Surgical, Inc. (ISRG - Free Report) has a Growth Score of B.
In the past three months, shares of Intuitive Surgical have gained 10.1%, outperforming the industry’s decline of 13.7%.
The California-based company, with a Zacks Rank #1, recently announced that it is commencing direct operations in India through distributor Vattikuti Technologies Pvt. Ltd. Moreover, the company’s flagship da Vinci SP surgical system for urologic surgical procedures was recently approved by the FDA.
In the last 60 days, the Zacks Consensus Estimate for Intuitive Surgical’s earnings per share rose 3.8% to $2.43.
Abiomed, Inc. has a Zacks Rank #1 and a Growth Score of B. You can see see the complete list of today’s Zacks #1 Rank stocks here.
In the past three months, shares of Abiomed have gained 38.5%, outperforming the industry’s decline of 13.7%.
The Massachusetts-based company recently replaced Wyndham Worldwide Corp. on the S&P 500 list.
In the last 60 days, the Zacks Consensus Estimate for Abiomed’s earnings per share rose 1.3% to 80 cents.
Varian Medical Systems, Inc. has a Zacks Rank #2 and a Growth Score of B.
In the past six months, shares of Varian Medical have rallied 7.6%, faring better than the industry’s fall of 7.2%.
The California-based provider of radiotherapy solutions has of late been targeting expansion in Africa. The company’s coveted Halcyon system has been adopted by three different cancer centers in northern and southern Africa. Furthermore, Varian Medical recently signed a software technology training and education cooperation agreement with the Brazil Ministry of Health (MOH) and seven universities and science and technology institutions (ICTs) in Brazil.
Over the last 60 days, the Zacks Consensus Estimate for Varian Medical’s earnings per share remained stable.
Surmodics, Inc. (SRDX - Free Report) has a Zacks Rank #2 and a Growth Score of A.
In the past six months, shares of Surmodics have gained 60.2%, outperforming the industry’s growth of 10.1%.
The Minnesota-based provider of medical device recently signed an agreement with Embolitech to acquire an innovative thrombectomy platform technology and related intellectual property with broad potential peripheral vascular applications. It will enhance the company’s focus on developing highly differentiated whole-product solutions.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>